Submit your article to this journal Results: PCO rats exhibited ovarian cystogenesis which was preserved by the application of carvedilol and ANGIPARSä. In comparison with controls, decreased level of the total antioxidant power (TAP) and higher levels of reactive oxygen species (ROS) and lipid peroxidation (LPO) in serum and ovaries (2.41 ± 0.67 versus 0.72 ± 0.11; and 0.17 ± 0.04 versus 0.05 ± 0.01; 5.48 ± 1.30 versus 10.56 ± 0.77; and 7.06 ± 1.94 versus 17.98 ± 0.98; p50.05, respectively) were detected in PCO rats. Moreover, the PCO rats exhibited hyperandrogenism due to a 3.7-fold increase in serum testosterone concentration (35.04 ± 3.17 versus 131.09 ± 13.24; p50.05) along with a 2.98-fold decrease in serum progesterone (6.19 ± 0.40 versus 18.50 ± 1.03; p50.05) and 5.2-fold decrease in serum estradiol (9.30 ± 0.61 versus 48.3 ± 2.10; p50.05) when compared with those of the control group. However, similar to the control group, normal levels of OS markers and sex hormones were detected in ANGIPARSä and carvedilol co-treated PCO rats. Besides, when compared with controls, increased levels of TNF-a (770.75 ± 42.06 versus 477.14 ± 28.77; p50.05) and insulin (1.27 ± 0.10 versus 0.36 ± 0.05; p50.05) in PCO rats were significantly inhibited by carvedilol and ANGIPARSä co-treatment. Discussion and conclusion: We evidenced the beneficial effects of carvedilol and ANGIPARSä in PCO, which underpin the new alternative approach in using these kinds of medicines in female reproductive disorders.